Mabcure Stock Fundamentals
| MBCI Stock | USD 0.0001 0.00 0.00% |
MabCure fundamentals help investors to digest information that contributes to MabCure's financial success or failures. It also enables traders to predict the movement of MabCure Pink Sheet. The fundamental analysis module provides a way to measure MabCure's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MabCure pink sheet.
MabCure |
MabCure Company Return On Asset Analysis
MabCure's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current MabCure Return On Asset | -0.0422 |
Most of MabCure's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MabCure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, MabCure has a Return On Asset of -0.0422. This is 98.54% lower than that of the Technology sector and 99.41% lower than that of the Solar industry. The return on asset for all United States stocks is 69.86% lower than that of the firm.
MabCure Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining MabCure's current stock value. Our valuation model uses many indicators to compare MabCure value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MabCure competition to find correlations between indicators driving MabCure's intrinsic value. More Info.MabCure is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value MabCure by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for MabCure's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.MabCure Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MabCure's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MabCure could also be used in its relative valuation, which is a method of valuing MabCure by comparing valuation metrics of similar companies.MabCure is currently under evaluation in return on asset category among its peers.
MabCure Fundamentals
| Return On Equity | -1.25 | |||
| Return On Asset | -0.0422 | |||
| Operating Margin | (1.42) % | |||
| Current Valuation | 643.64 K | |||
| Shares Outstanding | 64.36 M | |||
| Price To Earning | (0.02) X | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 1.29 X | |||
| Revenue | 500 K | |||
| Gross Profit | 500 K | |||
| EBITDA | (12.05 M) | |||
| Net Income | (12.26 M) | |||
| Cash And Equivalents | 146.44 K | |||
| Total Debt | 304.98 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.17 X | |||
| Book Value Per Share | 0.06 X | |||
| Cash Flow From Operations | (61.39 K) | |||
| Earnings Per Share | (0.19) X | |||
| Beta | 0.0893 | |||
| Market Capitalization | 643.64 K | |||
| Total Asset | 4.81 M | |||
| Z Score | -5.4 | |||
| Net Asset | 4.81 M |
About MabCure Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MabCure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MabCure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MabCure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. MabCure Inc. was founded in 2006 and is based in White Plains, New York. Mabcure is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in MabCure Pink Sheet
MabCure financial ratios help investors to determine whether MabCure Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MabCure with respect to the benefits of owning MabCure security.